Objective:

Review evidence on lifitegrast ophthalmic solution 5% for dry eye disease (DED), including its mechanism, efficacy, safety, real-world use, and emerging applications.

Approach:

• Mechanism: The review describes lifitegrast as an LFA-1 antagonist that blocks interaction with ICAM-1, interfering with T-cell activation, migration, and inflammatory cytokine release.
• Evidence reviewed: The authors synthesize clinical trial, safety, pharmacovigilance, and real-world evidence, including results from three 12-week phase 3 OPUS trials.

Key Findings:

• OPUS-1 found significant improvement in inferior corneal staining versus vehicle; secondary endpoints included improvements in eye dryness and ocular discomfort.
• OPUS-2 did not meet its corneal staining coprimary endpoint but found significant improvement in eye dryness, apparent by day 14.
• OPUS-3 found significant improvement in eye dryness by day 14, maintained at later assessments. A pooled post hoc analysis of OPUS-2 and OPUS-3 found greater odds of clinically meaningful improvement in staining and dryness with lifitegrast.
• Across five randomized trials involving 2,464 patients, common ocular adverse events included instillation-site irritation, reaction, and pain. Dysgeusia occurred in 14.5% of lifitegrast-treated patients versus 0.3% receiving vehicle; adverse-event discontinua…
• Real-world studies generally reported improvements in symptoms, signs, and quality of life, while treatment persistence remained a challenge.
• A prospective case series reported mean OSDI improvement from 52.2 at baseline to 31.2 after 12 weeks, alongside improvements in several tear and ocular-surface measures.
• The review describes emerging use for preoperative ocular-surface optimization before cataract surgery, with reported improvements in keratometry reproducibility and refractive accuracy.

Interpretation:

The review authors position lifitegrast as one option in a personalized DED treatment landscape. They note that signs and symptoms may diverge in this heterogeneous disease and suggest inflammatory biomarkers and advanced imaging may help identify patients most likely to benefit.

Limitations:

• The review reports divergent sign and symptom outcomes across trials and notes the often weak relationship between objective findings and patient-reported symptoms.
• The review received Bausch + Lomb-funded medical writing assistance; its authors are company employees, and several others reported consultancy relationships.

Sources:

• Article context provided